pexmetinib   

GtoPdb Ligand ID: 9917

Synonyms: ARRY-614 | ARRY614
Compound class: Synthetic organic
Comment: Pexmetinib is an orally bioavailable small-molecule inhibitor of p38 MAPK (β isoforms) and Tie2 kinases [2]. It is a type 2 kinase inhibitor that binds both Tie2 and p38 MAP kinases in the "DFG-out" conformation. p38 MAPK is a proinflammatory kinase, Tie2 is an endothelial cell specific receptor tyrosine kinase and is the receptor for angiopoietin-1. Concomitant inhibition of these kinases is predicted to produce antineoplastic, anti-inflammatory and antiangiogenic effects that would provide a novel anti-cancer therapeutic, in particular for the treatment of myelodysplastic syndromes (MDS) [1,4] and acute myeloid leukemia (AML).
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 105.71
Molecular weight 556.26
XLogP 5.49
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Canonical SMILES OCCn1ncc2c1ccc(c2)Oc1ccc(cc1CNC(=O)Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)F
Isomeric SMILES OCCn1ncc2c1ccc(c2)Oc1ccc(cc1CNC(=O)Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)F
InChI InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,39H,13-14,18H2,1-4H3,(H2,33,35,40)
InChI Key LNMRSSIMGCDUTP-UHFFFAOYSA-N
No information available.
Summary of Clinical Use
Phase 1 clinical studies designed to evaluate ARRY-614's efficacy in myelodysplastic syndromes have been completed (see NCT01496495 and NCT00916227). Results from NCT00916227 showed that ARRY-614 was well tolerated, and exhibited a level of efficacy to justify further evaluation [3]. Despite this, there are no more advanced clinical trials registered with ClinicalTrials.gov (April 2018).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00916227 A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome Phase 1 Interventional Array BioPharma
NCT01496495 A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes Phase 1 Interventional Array BioPharma